

ASX ANNOUNCEMENT

ALLIED ANNOUNCES ADDITIONAL EARLY ACCESS FOR CARDIOCEL®

- **Prof. Christian Brizard and colleagues gain early access to CardioCel® within an investigator initiated clinical trial scheme in CHD**
- **Dr Nelson Alphonso now using CardioCel® under the Authorised Prescriber Scheme**
- **Allied anticipates CardioCel® CE mark mid-2013**

Brisbane, Australia, 8th of April 2013

Allied Healthcare Group (ASX: AHZ) today announced the number of Australian surgeons who are actively using, or who have gained TGA pre market authorisation to use CardioCel® for the treatment and repair of congenital heart disease (CHD) has increased from one to five.

A number of additional surgeons are also engaged in the application process to use CardioCel® via the Authorised Prescriber Scheme (APS).

Dr Nelson Alphonso, Director of Paediatric Cardiac Surgery at the Mater Hospital in Brisbane has also received TGA authorisation to use CardioCel® for treating and repairing congenital heart defects under the APS and he joins Dr Tom Karl, also based at the Mater, who was the first to be APS approved, to use CardioCel®.

Professor Christian Brizard, of Melbourne University, along with his colleagues, have gained early access to CardioCel® under a trial at a Melbourne based hospital. The purpose of this new investigator-led clinical study is to expand the access to CardioCel® in Australia. The early access clinical trial scheme will enroll up to 40 patients with CHD.

"As indicated previously there are a number of surgeons in Australia that see the clinical benefits of CardioCel® and a growing number of these have been working within their institutions to find a way to gain early access to CardioCel®. With five surgeons now successfully using it in CHD pre-approval to treat and repair these heart defects," said Managing Director Lee Rodne.

Congenital heart disease is a leading cause of mortality in infants globally. In Australia 6 children are born with congenital heart disease every day and over 40,000 born each year in the US.

"Key opinion leaders in the field of Cardiothoracic surgery in Asia Pacific, Europe and US realise CardioCel® is the next logical step in the treatment of CHD patients. We now have Advisory Boards in the three jurisdictions and as soon as possible they will be using CardioCel® in their centers for its anti-calcification profile, regenerative properties and ease of handling," said Bob Atwill, Group Executive, and Regenerative Medicine Division CEO.

Allied is aware of several other Australian surgeons who are pursuing access for CardioCel® under the Authorised Prescriber Scheme and will provide updates on a regular basis.



CardioCel® has unique properties making it suited to use by surgeons as a regenerative cardiac repair tissue, as well as delivering key benefits to patients compared to existing surgical approaches. Videos on CardioCel® can be viewed at:

<http://www.alliedhealthcaregroup.com.au/video>

For more information, please contact:

Dr Julian Chick, Chief Operating Officer Allied Healthcare Group Tel: +61 3 9620 5454

Bob Atwill, Allied Healthcare Group Executive, Regenerative Medicine Division CEO
Tel: +61 448 778 880

Media:
Shevaun Cooper
Buchan Consulting
+61 39866 4722
scooper@buchanwe.com.au

About Allied Healthcare Group Limited

Allied Healthcare Group Limited (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from Research & Development through Clinical Development as well as Sales, Marketing and Distribution.

Allied Healthcare Group is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Allied also has major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential like Herpes and Human Papilloma virus.

Further information on the Company can be found on www.alliedhealthcaregroup.com.au.

Allied's Regenerative Medicine Division

Allied's regenerative tissue engineering technology started as a research program in in 2001 focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT® Tissue Engineering Process. The lead programme CardioCel® has successfully completed a number of animal studies and a Phase II human clinical trial. CardioCel® is a cardiovascular patch used to repair paediatric heart deformities. These deformities range from routine "Hole in the Heart" operations to major vessel outflow tract repairs. The CardioCel® patch may also be used to repair leaking heart valves in paediatric patients. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration*, suggesting that CardioCel® facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.



The division is based on the patented ADAPT® Tissue Engineering Process as a platform technology to produce implantable tissue patches for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT® technology is used to process animal derived tissues to produce unique implantable tissue patches that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post implantation. This technology has the potential for medical professionals to use regenerative products instead of synthetic products currently used in soft tissue repair.

* Körbling & Estrov, 2003. Adult Stem Cells for Tissue Repair — A New Therapeutic Concept? NEJM Volume 349:570-582, August 7, 2003, Number 6

